Molecular Diagnostics

Cancer according to WHO

The World Health Organization (WHO) states that as many as 30% of all cancers could be cured if diagnosed earlier. One reason for this is that tumors in early stages more frequently are surgically removable and better subjected to other treatment strategies. In the early 1980´s, the introduction of mammography for earlier detection of breast tumors contributed to an improved five-year survival rate of >85%.

Early treatment

If cancers could be detected before clinical symptoms arise, surgery and cancer therapy would have an increased efficacy leading to improved survival. Being able to diagnose cancer earlier, based on a simple blood test, would open up for new possibilities in cancer treatment.

Our solution

By using a multiplexed microarray platform developed at the Department of Immunotechnology, protein patterns, so called signatures, can be analyzed in serum, other bio fluids or tissue associated with different cancers. This platform has been validated in more than 20 different clinical studies, mostly in different cancer indications, but also in autoimmunity and infectious disease.

The design and ability to produce a high quality multiplexed antibody microarray is based on over 20 years of experience with recombinant antibody libraries. Molecular diagnostics will contribute to define the following

  1. early diagnosis of patients at risk
  2. prognostication of treatment efficacy
  3. evidence-based treatment strategies

This will be performed by the multiplexed analysis of serum in combination with advanced bioinformatics, which will result in the deciphering of complex protein patterns associated with clinical parameters.

Page Manager: jana.hladilkova@immun.lth.se | 2021-03-19